Americas Cancer Biological Therapy market information, by type (Monoclonal Antibodies, Gene Therapy, Colony-Stimulating Factors, Targeted Therapy and Others) by end users (hospitals & clinics, cancer research centers, laboratories) - Forecast to 2032

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL

5.1.1 BARGAINING POWER OF SUPPLIERS

5.1.2 BARGAINING POWER OF BUYERS

5.1.3 THREAT OF NEW ENTRANTS

5.1.4 THREAT OF SUBSTITUTES

5.1.5 INTENSITY OF RIVALRY

5.2 SUPPLY CHAIN ANALYSIS

6 AMERICAS CANCER BIOLOGICAL THERAPY MARKET, BY TYPES

6.1 MONOCLONAL ANTIBODIES

6.1.1 NAKED MONOCLONAL ANTIBODIES

6.1.2 CONJUGATED MONOCLONAL ANTIBODIES

6.1.3 OTHER

6.2 INTERFERONS

6.3 INTERLEUKINS

6.4 CANCER GROWTH INHIBITORS

6.4.1 TYROSINE KINASE INHIBITORS

6.4.2 MTOR INHIBITORS

6.4.3 PROTEASOME INHIBITORS

6.5 GENE THERAPY

6.6 COLONY-STIMULATING FACTORS

6.7 TARGETED THERAPY

6.8 CANCER VACCINES

6.8 OTHERS

7 AMERICAS CANCER BIOLOGICAL THERAPY MARKET, BY END USER

7.1 HOSPITALS & CLINICS

7.2 CANCER RESEARCH CENTERS

7.3 LABORATORIES AND OTHERS

8 AMERICAS CANCER BIOLOGICAL THERAPY MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 US

8.1.2 CANADA

8.1.3 REST OF AMERICA

9 COMPANY PROFILE

9.1 F. HOFFMANN-LA ROCHE AG

9.1.1 OVERVIEW

9.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

9.1.3 FINANCIAL UPDATES

9.1.4 KEY DEVELOPMENTS

9.2 NOVARTIS INTERNATIONAL AG

9.2.1 OVERVIEW

9.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

9.2.3 FINANCIAL UPDATES

9.2.4 KEY DEVELOPMENTS

9.3 ELI LILLY

9.3.1 OVERVIEW

9.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

9.3.3 FINANCIAL UPDATES

9.3.4 KEY DEVELOPMENTS

9.4 GSK

9.4.1 OVERVIEW

9.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

9.4.3 FINANCIAL UPDATES

9.4.4 KEY DEVELOPMENTS

9.5 MERCK & CO

9.5.1 OVERVIEW

9.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

9.5.3 FINANCIAL UPDATES

9.5.4 KEY DEVELOPMENTS

9.6 AMGEN INC

9.6.1 OVERVIEW

9.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

9.6.3 FINANCIAL UPDATES

9.6.4 KEY DEVELOPMENTS

9.7 OTHER